European Antimicrobial Resistance Surveillance Network

European Antimicrobial Resistance Surveillance Network
Name	European Antimicrobial Resistance Surveillance Network
Founded	1998
Headquarters	Stockholm, Sweden
Parent	European Centre for Disease Prevention and Control
Website	[https://www.ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratory-networks/ears-net EARS-Net]

European Antimicrobial Resistance Surveillance Network. It is a comprehensive public health monitoring system coordinated by the European Centre for Disease Prevention and Control to track the spread of antimicrobial resistance across the continent. Established in the late 1990s, the network aggregates laboratory data from national surveillance systems to inform policy and guide clinical practice. Its work is critical for understanding trends in resistant pathogens like methicillin-resistant Staphylococcus aureus and guiding the implementation of Antimicrobial stewardship programs.

Background and establishment

The network was initiated in 1998 under the auspices of the European Commission and the World Health Organization Regional Office for Europe, responding to growing concerns over treatment failures. Its creation was influenced by earlier collaborative projects like the European Antimicrobial Resistance Surveillance System and aligned with broader European Union health strategies. The operational management was later transferred to the newly formed European Centre for Disease Prevention and Control in Stockholm following its establishment in 2005, integrating it into the European Union's formal public health infrastructure.

Objectives and scope

The primary objective is to collect comparable and reliable data on antimicrobial resistance from all participating European Union member states and European Economic Area countries. It focuses on invasive isolates of key bacterial pathogens, including Streptococcus pneumoniae, Escherichia coli, and Klebsiella pneumoniae, from blood and cerebrospinal fluid. The network aims to detect emerging resistance threats, assess the burden of Healthcare-associated infection, and evaluate the impact of national action plans like those developed under the Global Action Plan on Antimicrobial Resistance.

Surveillance methodology

The network employs a standardized protocol where national reference laboratories in countries like Robert Koch Institute in Germany and Public Health England submit aggregated data. This involves routine susceptibility testing of bacterial isolates using methods aligned with the European Committee on Antimicrobial Susceptibility Testing breakpoints. Data on specific antimicrobial agents, such as resistance to carbapenems in Pseudomonas aeruginosa, are collected annually and validated through external quality assurance programs organized by the European Centre for Disease Prevention and Control.

Key findings and reports

Annual reports have consistently highlighted a north-to-south and west-to-east gradient in resistance rates across Europe, with higher prevalence often reported in the Mediterranean Basin and parts of Eastern Europe. Significant trends include the rapid spread of carbapenem-resistant Enterobacteriaceae and the concerning stability of vancomycin-resistant Enterococcus rates. These publications are referenced by major bodies like the Organisation for Economic Co-operation and Development and inform the work of the World Health Organization on its Priority pathogens list.

Governance and collaboration

Governance is overseen by the European Centre for Disease Prevention and Control through a dedicated program manager and a network of nominated representatives from each participating country. It collaborates closely with other European Union surveillance networks, such as the European Surveillance of Antimicrobial Consumption Network and the Healthcare-associated infections surveillance network. External partnerships include joint projects with the Centers for Disease Control and Prevention and alignment with initiatives of the World Organisation for Animal Health.

Impact and future directions

The network's data have directly influenced European Union legislation and policy, including the development of the One Health approach to antimicrobial resistance. Its findings underpin the European Union's cross-border health threats decision and guide research priorities for entities like the Innovative Medicines Initiative. Future directions include enhancing genomic surveillance through integration with the European COVID-19 Data Platform, expanding monitoring to the Western Balkans, and strengthening links with Food and Agriculture Organization surveillance systems.

Category:European Union agencies Category:Public health organizations Category:Antimicrobial resistance